Release 5 Preview #1

This page is part of the FHIR Specification (v4.2.0: R5 Preview #1). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.4.2.1070 HL7 v3 Value Set substanceAdminSubstitution

Vocabulary Work Group Maturity Level: N/AExternal Use Context: Any

This value set (http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL:http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution
Version:2019-07-31
Name:v3.substanceAdminSubstitution
Title:v3 Code System substanceAdminSubstitution
Definition:

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

OID: (for OID based terminology systems)
Source ResourceXML / JSON

This value set is used in the following places:

4.4.2.1070.1 Content Logical Definition

This value set includes codes from the following code systems:

 

4.4.2.1070.2 Expansion

This expansion generated 31 Dec 2019

This value set contains 9 concepts

Expansion based on http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution version 2019-07-31

All codes from system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

LvlCodeDisplayDefinition
0_ActSubstanceAdminSubstitutionCodeActSubstanceAdminSubstitutionCodeDescription: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
1  EequivalentDescription: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
2    ECequivalent compositionDescription: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
3      BCbrand compositionDescription: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
3      Ggeneric compositionDescription: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
2    TEtherapeutic alternativeDescription: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
3      TBtherapeutic brandDescription: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
3      TGtherapeutic genericDescription: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
1  FformularyDescription: This substitution was performed or is permitted based on formulary guidelines.
1  NnoneNo substitution occurred or is permitted.